Drug Profile
Research programme: OX40 agonists - Apogenix
Alternative Names: HERA OX40LLatest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Apogenix
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action OX40 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Solid tumours in Germany (unspecified route) (Apogenix pipeline, August 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Solid-tumours in Germany
- 06 Sep 2017 Pharmacokinetics data from preclinical studies in Solid tumours released by Apogenix